Reprogramming away from the exhausted T cell state
- PMID: 26589493
- DOI: 10.1016/j.smim.2015.10.007
Reprogramming away from the exhausted T cell state
Abstract
Induced pluripotent stem cells (iPSCs) describe somatic cells that have been reprogrammed to the pluripotent state from which they can then be differentiated into any cell type of the body. This ability has tremendous implications on a wide number of medical sciences and applications, including cancer treatments. In many cancer patients, tumor infiltrating lymphocytes (TILs) have reached an exhausted state and are unable to exert effector function despite detecting and localizing at the tumor. Although the isolation, ex vivo expansion and transplantation of TILs is effective in a significant group of patients, too many patients do not respond positively to this treatment, in part because the expanded TIL population does not include a sufficient number of cells with the naïve or memory phenotype. Cell reprogramming using iPSC technologies aims to overcome this problem by returning TILs to the pluripotent state from which they can be differentiated into a heterogeneous population of T cells that are best suited to combat the tumor.
Keywords: Adoptive cellular immunotherapy; Cell reprogramming; Exhaustion; Induced pluripotent stem cells; T-iPSCs.
Copyright © 2015 Elsevier Ltd. All rights reserved.
Similar articles
-
[Pluripotent stem cells as a source for T cell research and clinical application].Nihon Rinsho Meneki Gakkai Kaishi. 2015;38(2):101-8. doi: 10.2177/jsci.38.101. Nihon Rinsho Meneki Gakkai Kaishi. 2015. PMID: 26016637 Review. Japanese.
-
Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes.J Vis Exp. 2016 Nov 11;(117):54375. doi: 10.3791/54375. J Vis Exp. 2016. PMID: 27911363 Free PMC article.
-
Human iPSC Generation from Antigen-Specific T Cells.Methods Mol Biol. 2019;2048:53-57. doi: 10.1007/978-1-4939-9728-2_5. Methods Mol Biol. 2019. PMID: 31396928
-
Reprogramming of Tumor-reactive Tumor-infiltrating Lymphocytes to Human-induced Pluripotent Stem Cells.Cancer Res Commun. 2023 May 25;3(5):917-932. doi: 10.1158/2767-9764.CRC-22-0265. eCollection 2023 May. Cancer Res Commun. 2023. PMID: 37377887 Free PMC article.
-
Rise of iPSCs as a cell source for adoptive immunotherapy.Hum Cell. 2014 Apr;27(2):47-50. doi: 10.1007/s13577-014-0089-8. Epub 2014 Feb 9. Hum Cell. 2014. PMID: 24510519 Review.
Cited by
-
Application of Chimeric Antigen Receptor T Cells in the Treatment of Hematological Malignancies.Biomed Res Int. 2020 Oct 1;2020:4241864. doi: 10.1155/2020/4241864. eCollection 2020. Biomed Res Int. 2020. PMID: 33062678 Free PMC article. Review.
-
iPSCs in NK Cell Manufacturing and NKEV Development.Front Immunol. 2022 Jul 8;13:890894. doi: 10.3389/fimmu.2022.890894. eCollection 2022. Front Immunol. 2022. PMID: 35874677 Free PMC article. Review.
-
Advances in Adoptive Cell Therapy Using Induced Pluripotent Stem Cell-Derived T Cells.Front Immunol. 2021 Sep 28;12:759558. doi: 10.3389/fimmu.2021.759558. eCollection 2021. Front Immunol. 2021. PMID: 34650571 Free PMC article. Review.
-
The 3 I's of immunity and aging: immunosenescence, inflammaging, and immune resilience.Front Aging. 2024 Oct 16;5:1490302. doi: 10.3389/fragi.2024.1490302. eCollection 2024. Front Aging. 2024. PMID: 39478807 Free PMC article. Review.
-
T-Cell Progenitors As A New Immunotherapy to Bypass Hurdles of Allogeneic Hematopoietic Stem Cell Transplantation.Front Immunol. 2022 Jul 7;13:956919. doi: 10.3389/fimmu.2022.956919. eCollection 2022. Front Immunol. 2022. PMID: 35874778 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
